GERMANTOWN, Md., Nov. 18, 2013 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointments of Vice President, Business Development for Europe and Asia Peter Seufer-Wasserthal, Ph.D., and Chief Information Officer Dana Di Ferdinando, effective immediately.
Intrexon Chief Operating Officer Krish Krishnan welcomed Ms. Di Ferdinando and Dr. Seufer-Wasserthal: "We are excited to have Ms. Di Ferdinando and Dr. Seufer-Wasserthal join Intrexon at this stage of our growth. Dana will lead development of the next generation of Intrexon's proprietary technologies, particularly UltraVector®, an industry-leading software platform that enables our collaborators to design, test, and produce complex biological solutions with the goal of generating superior commercial products. Peter will expand Intrexon's presence even further into Europe and Asia, growing our international relationships to establish additional collaborations abroad. I am confident that their respective professional experiences and insights will be a tremendous asset to Intrexon."
Dr. Seufer-Wasserthal will broaden Intrexon's European and Asian market sectors in Food, Health, Energy and Environment, establishing Exclusive Channel Collaborations and other research and development opportunities. Prior to joining Intrexon, Dr. Seufer-Wasserthal was Senior Vice President of Pharmaceuticals at Codexis, Inc., where he was responsible for closing numerous licensing, research and supply agreements, and adapting IP strategy to increase account penetration. Before Codexis, Inc., Dr. Seufer-Wasserthal managed drug discovery collaborations, licensed pre-clinical candidates and purchased services for drug development projects as Senior Vice President of Clinical Development at Morphochem AG. He holds a Ph.D. in organic chemistry from the Technical University of Graz.
Ms. Di Ferdinando brings to Intrexon more than 25 years of professional experience in the management, engineering, analysis and implementation of integrated solutions for life sciences and technology companies. Most recently, she was CIO at Arena Pharmaceuticals, where she managed IT functions and oversaw enterprise business technology initiatives and application development efforts at Arena's U.S., European and Asian locations. Prior to Arena, Ms. Di Ferdinando worked for major consulting and analytics companies Deloitte & Touche and Science Applications International Corporation (SAIC). Ms. Di Ferdinando holds a B.S. in Computer Science from Rutgers University and an M.S. in Operations Research from Stanford University.
About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy and the Environment to create biologically-based products that improve the quality of life and the health of the planet. Through the company's proprietary UltraVector® platform, Intrexon provides its partners with industrial-scale design and development of complex biological systems. The UltraVector® platform delivers unprecedented control over the quality, function, and performance of living cells. We call our synthetic biology approach and integrated technologies Better DNA®, and we invite you to discover more at www.dna.com.
Trademarks Intrexon, UltraVector, RheoSwitch Therapeutic System, RTS and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.
Intrexon Corporation Contact: Peter McLaughlin Vice President, Corporate Communications Tel: +1 323-842-7779 PublicRelations@intrexon.com
SOURCE Intrexon Corporation